Industry Briefs: August 20, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: August 20, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Antares Vision and Xyntek have formed a partnership for e-pedigree and serialization turnkey capabilities. Read More

Cambrex has agreed to supply an API for a customer’s Phase III program. The agreement is expected to contribute more than $20 million in revenues to Cambrex, which will expand its large-scale multipurpose cGMP assets in 2012 and 2013. Read More

Onyx Scientific and Molecular Profiles have formed an agreement to deliver end-to-end services from initial drug discovery to early- and late-phase manufacturing. Read More

Parker Hannifin has agreed to acquire SciLog, a provider of sensor technology and automated lab-scale and production systems for the biopharmaceutical industry.

FDA has approved Sanofi’s Auvi-Q (epinephrine injection), a voice-activated autoinjector for treating allergic reactions in people who are at risk for anaphylaxis. Read More

Sun Pharmaceutical has agreed to acquire Taro Pharmaceutical. Read More

TG Therapeutics and Rhizen Pharmaceutical have agreed to collaborate on the development and commercialization of Rhizen’s lead product candidate, a novel PI3K delta inhibitor, TGR-1202 (previously referred to as RP5264). Read More

People Notes

Avantor Performance Materials has named John M. Steitz president and CEO. Read More

ChanTest has appointed Chris Mathes as chief commercial officer. Read More

INC Research has named Jamie Macdonald CEO. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here